2023 TUMOR SECTION SYMPOSIUM

BRAIN AND SPINE RECURRENT TUMORS: THE NEUROSURGEON’S ROLE

PRELIMINARY PROGRAM

SEPTEMBER 8-9, 2023
WASHINGTON, D.C.

SAVE WHEN YOU REGISTER BY AUGUST 9! MEDICAL STUDENTS REGISTER NOW AND ENJOY FREE REGISTRATION. CNS.ORG/TUMOR

Register for both the 2023 CNS Annual Meeting and Tumor Section Symposium and receive a $100 discount on each meeting for a total savings of $200!
DEAR COLLEAGUES,

We are excited to invite you to Washington, D.C., September 8-9, for the 16th Biennial Tumor Section Symposium, which immediately precedes the 2023 CNS Annual Meeting. Our theme this year is Brain and Spine Recurrent Tumors: The Neurosurgeon’s Role.

This two-day event will offer four engaging scientific sessions led by global experts in the field, four original science sessions, and a Friday night Gala Reception, Dinner, and Awards. Recognizing the increasing role of Advanced Practice Providers (APPs) in the care of neurosurgical oncology patients, we inaugurate a special session each day focused on APPs. We hope to welcome your APPs during these sessions and have them partake in the entire meeting with us.

Join us as we explore novel treatments and controversies on recurrent low-grade gliomas, glioblastoma, meningiomas, and brain and spine metastatic disease. We look forward to your participation during the case discussion panels. The meeting also explores immune- and viral-based therapies for CNS recurrent tumors, and how molecular profiling and non-invasive biomarkers detection can be leveraged to improve patient care at the time of tumor recurrence.

We are also thrilled to present our world-renowned 2023 Keynote Speakers: David Louis and Evanthia Galanis who will review the implications of the new WHO classification at the time of recurrence and trial opportunities leading to breakthrough novel treatments for our patients.

The Friday evening Gala takes place at the luxurious Renaissance Washington, D.C. Downtown Hotel. It is the perfect setting to mingle with colleagues, patients, advocate group representatives, and friends. The Tumor Section’s Career Awards for distinguished service (The Mark Rosenblum Distinguished Service Award), career accomplishments (The Charles B. Wilson Award), and mentoring (The Andrew T. Parsa Mentorship Award) will be presented, along with certificates for best oral and poster presentations from each of the four open abstract sessions during the two days.

The symposium takes place at the Walter E. Washington Convention Center in the heart of downtown Washington, D.C. Take time to explore the Washington auto show, D.C. History Center, National Portrait Gallery, City Brew Tours, the National Museum of Women in the Arts, and so much more.

We encourage you to stay for the 2023 CNS Annual Meeting, September 9-13, which provides more opportunities for learning and networking with colleagues. When you register for both the Tumor Section Symposium and CNS Annual Meeting together, you will receive an automatic $100 discount on each meeting for a total savings of $200.

We can’t wait to see you in Washington, D.C.!

Sincerely,

Chair, Joint Section on Tumors
Isabelle M. Germano, MD, MBA
Icahn School of Medicine at Mount Sinai
New York, NY

Scientific Meeting Chair
Gelareh Zadeh, MD
University of Toronto
Toronto, Canada

Scientific Meeting Co-chair
Chetan Bettegowda, MD, PhD
John Hopkins University
Baltimore, MD

Scientific Meeting Co-chair
Pablo Recinos, MD
Cleveland Clinic
Cleveland, OH
Friday, September 8 • 8:00 am-5:30 pm

8:00–9:00 am
Neurosurgical Oncology Advanced Practice Providers Course Day 1
Perspectives on the Roles and Dynamics of APPs in Neurosurgical Oncology
Introduction: The APP Role in Neurosurgical Oncology
Isabelle M. Germano
The APP’s Perspective
Natalie J. Hall
The Neurosurgeon’s Perspective
Walavan Sivakumar
The Trainee’s Perspective
Heather C. Grimaudo
Question and Answer

9:00–9:05 am
Introduction to the Tumor Section Symposium
Isabelle M. Germano

9:06–9:12 am
Introduction to the Scientific Program Day 1
Gelareh Zadeh

9:13–10:20 am
General Session I: Prediction of Recurrence and Treatment Response in Gliomas
Moderators: Ian Parney, Analiz Rodriguez
Targeted Therapeutics at Glioma Recurrence
Dan Cahill
Intraoperative Innovations Guiding Cavitary Therapeutics
Michael Vogelbaum
Predictors of Response to Immunotherapy
Michael Lim
Biomarker Determinants of Treatment Failure
Chetan Bettegowda

11:05 am–1:35 pm
Abstract Session I: Recurrent Gliomas/Translational Research
Moderators: Ian Parney, Analiz Rodriguez
Top abstracts on this topic to be presented

11:30 am–12:00 pm
Keynote Speaker: The Updated WHO Classification and its Implications at the Time of Tumor Recurrence
David Louis, Harvard School of Medicine

1:35–2:45 pm
General Session II: Prediction and Treatment of Recurrent Meningiomas
Moderators: Jennifer Moliterno-Gunel, Gabe Zada
Predicting Disease Behavior and Recurrence
Farshad Nassiri
Predicting Response to Radiation
Albert Kim
Molecular Clinical Trials for Recurrent Meningiomas
Fred Barker
Surgical Considerations for Recurrent Meningiomas
Pablo Recinos
Complication Avoidance
Daniel M. Prevedello

3:30–3:55 pm
Abstract Session II: Meningiomas/ Clinical Research
Moderators: Daniel M. Prevedello, Brad Zacharia
Top abstracts on this topic to be presented

3:55–4:45 pm
Case Discussion I: Recurrent Gliomas
Moderators: Desmond Brown, Maryam Rahman
Introduction to Case Discussion
Maryam Rahman
Molecular Profile of Recurrent Glioma
Gavin Dunn
Immunoviotherapy of Recurrent Glioma
Manish Aghi
Utility of Biomarker Driven Decision Making
Brian V. Nahed

4:45–5:30 pm
Case Discussion II: Recurrent Meningiomas
Moderators: Wenyua Linda Bi, Gabe Zada
Introduction to Case Discussion
Wenyua Linda Bi
Utility of Methylation Predictor in Radiation
Justin Wang
Molecular Profiling at Recurrence
Akash Patel
Use of Radiosurgery
Varun Kshettry

11:30 am–12:00 pm
Keynote Speaker: The Updated WHO Classification and its Implications at the Time of Tumor Recurrence
David Louis, Harvard School of Medicine

BE SURE TO CHECK OUT THE EXHIBITS DURING THESE BREAKS!

• 10:20–11:05 am
• 2:45–3:30 pm
What’s New Session
Presented by Elekta Inc., Neosoma Inc.
Saturday, September 9 • 7:00 am–6:00 pm

7:00–8:00 am
Neurosurgical Oncology: Advanced Practice Providers Course Day 2
Managing Expectations in Neurosurgical Oncology The APPs Role
Introduction: Managing Care Expectations
Isabelle M. Germano
Managing Expectations Pre-operatively
Leslie Schlachter
Managing Post-operative Expectations
Kenisha Blake
Managing the in-patient to out-patient gap
Amalia Eisenberg
Question and Answer

8:00–8:02 am
Introduction to the Scientific Program Day 2

8:03–8:35 am
Abstract Session III: Brain Mets: Intersection of Science and Surgery at Recurrence
Moderators: John Lee, Gordon Li
Top abstracts on this topic to be presented

8:35–9:40 am
General Session III: Brain Mets: Intersection of Science and Surgery at Recurrence
Moderators: Tiffany Hodges, Pascal O. Zinn
Endpoints of Clinical Trials
Nader Sanai
Immunotherapy Profile
Howard Colman
FUS and Brain Metastasis
Alexandra Golby
AI: Recurrence or Pseudo-progression
Joerg Christian Tonn

9:40–10:15 am
Keynote Speaker: Clinical Trials Options Consideration at the Time of Tumor Recurrence
Eva Galanis, Mayo Clinic

10:15–11:00 am
Case Discussion III: Brain Mets: Intersection of Science and Surgery at Recurrence
Moderators: Wajd Al-Holo, Isaac Yang
Panelists: Frank Attenello, Kaisorn Chaichana, Peter Fecci, Isaac Yang

11:00–11:45 am
Case Discussion III: Brain Mets: Intersection of Science and Surgery at Recurrence
Moderators: Wajd Al-Holo, Isaac Yang
Panelists: Frank Attenello, Kaisorn Chaichana, Peter Fecci, Isaac Yang

11:45 am–1:20 pm
Abstract Session III: Recurrent Brain Mets/Clinical Research
Moderators: Rohan Ramakrishna, Jeff Weinberg
Top abstracts on this topic to be presented

1:20–2:25 pm
General Session IV: Recurrent Spine Mets
Moderators: Ziya Gokasla, Randy Jensen
Surgical Indications: The Frail Patient
John Shin
The Role of Intra-operative Radiation
Nick Szerlip
The Role of LITT
Claudio Tatsui
Complication Avoidance at Re-operation
Nam Tran

2:35–3:15 pm
Abstract Session IV: Spine Mets/Translational Research
Moderators: Michael Galgano, Ilya Laufer
Top abstracts on this topic to be presented

3:15–4:00 pm
Case Discussion IV: Spine Mets
Moderators: Ben Elder, Claudio Tatsui
Recurrent in the Frail Patients
Camilo Molina
Recurrent After SRS/SBRT
Rory Goodwin
Recurrent at Multiple Sites
Larry Rhines
Discussion

4:00–4:45 pm
Breakout Sessions for Residents, Fellows, Medical Students, and Young Attendings
Breakout Session I: Navigating the FDA for IND/IDE
Moderator: Gautam Mehta
Panelist 1: Andrew Sloan
Panelist 2: Chris Cifarelli
Panelist 3: Isabelle M. Germano
Question and Answer

Breakout Session II: How to Establish a Translational Research Effort as an Early Career Neurosurgeon
Moderators: Maryam Rahman, Gelerah Zadeh
Panelist 1: James Markert
Panelist 2: Dan Orringer
Panelist 3: Mahua Dey
Question and Answer

Breakout Session III: Collaboration Across Colleges/Institutions
Moderator: Susan Pannullo
Panelist 1: Steven N. Kalkanis
Panelist 2: Alexandra Golby
Panelist 3: Brian Williams
Question and Answer

5:00–6:00 pm
Breakout Session for Residents, Fellows, Medical Students, and Young Attendings
Breakout Session I: Navigating the FDA for IND/IDE
Moderator: Gautam Mehta
Panelist 1: Andrew Sloan
Panelist 2: Chris Cifarelli
Panelist 3: Isabelle M. Germano
Question and Answer

Breakout Session II: How to Establish a Translational Research Effort as an Early Career Neurosurgeon
Moderators: Maryam Rahman, Gelerah Zadeh
Panelist 1: James Markert
Panelist 2: Dan Orringer
Panelist 3: Mahua Dey
Question and Answer

Breakout Session III: Collaboration Across Colleges/Institutions
Moderator: Susan Pannullo
Panelist 1: Steven N. Kalkanis
Panelist 2: Alexandra Golby
Panelist 3: Brian Williams
Question and Answer

BE SURE TO CHECK OUT THE EXHIBITS DURING THESE BREAKS!
- 10:15–11:00 am
- 3:15–4:00 pm

Program and faculty subject to change.
Accreditation

LEARNING OBJECTIVES

Upon completion of this symposium, participants will be able to:

■ Discuss advancements in technology and brain tumor science and relevance to treatment approaches and outcomes.
■ Develop innovative treatment strategies for patients with brain and spine tumors at diagnosis and recurrence.
■ Discuss advances in the evaluation and management of pituitary disease.
■ Recognize opportunities to develop as clinician-scientists.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Congress of Neurological Surgeons and the AANS/ CNS Section on Tumors. The CNS is accredited by ACCME to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT

The CNS designates this live activity for maximum of 15.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME CREDIT AND CERTIFICATE OF ATTENDANCE

CME credits can be claimed through the online system at www.cns.org/tumor. The CNS CME tracking system allows you to claim CME credit or Certificate of Attendance hours for the meeting. All attendees should only claim credit or hours of attendance commensurate with the extent of their participation in the activity.

CNS DISCLOSURE POLICY

The Congress of Neurological Surgeons controls the content and production of this CME activity and attempts to assure the presentation of balanced, objective information. In accordance with the Standards for Integrity and Independence in Accredited Continuing Education established by the Accreditation Council for Continuing Medical Education (ACCME), speakers are asked to disclose all relationships they have with ineligible companies* over the previous 24 months which may be related to the content of their lecture. The CNS reviews and mitigates all financial relationships before planners and faculty assume their role in the activity. A list of all relevant financial relationships listed for these participants will be posted and available to view prior to the meeting.

*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. An ineligible company is not eligible for ACCME accreditation or participation in Joint Providership.
WHO SHOULD ATTEND
Tumor neurological surgeons, residents, fellows, medical students, nurse clinicians, and physician assistants are welcome and encouraged to attend the Tumor Section Symposium. Educational sessions are directed toward these audiences and directly apply to their practices.

AIRPORT/GROUND TRANSPORTATION
The Tumor Section Symposium will take place at the Walter E. Washington Convention Center, which is located about 5 miles from Ronald Regan Washington National Airport (DCA), 30 miles from Dulles International Airport (IAD), and 40 miles from Baltimore/Washington International Thurgood Marshall Airport (BWI). Taxis are readily available outside Baggage Claim/Arrivals Level.

AMERICANS WITH DISABILITIES ACT
The Tumor Section ensures that no individual with a disability is excluded, denied services, segregated, or otherwise treated differently than other individuals because of the absence of auxiliary aids or services. If you require any of the auxiliary aids or services identified in the Americans with Disabilities Act in order to attend any program, please send your requirements directly to the CNS Meetings Department at meetings@cns.org, or by calling 847-240-2500.

WASHINGTON D.C. ATTRACTIONS
For information, please visit washington.org. The city offers a variety of fun activities and outstanding dining opportunities for the business traveler as well as families.

DISCLAIMER
The material presented at the 2023 Tumor Section Symposium has been made available by the Tumor Section for educational purposes only. The material is not intended to represent the only, nor necessarily the best, method or procedure appropriate for the medical situations discussed, but rather is intended to present an approach, view, statement, or opinion of the faculty which may be helpful to others who face similar situations.

Neither the content (whether written or oral) of any course, seminar, or other presentation in the program, nor the use of a specific product in conjunction therewith, nor the exhibition of any materials by any parties coincident with the program, should be construed as indicating endorsement or approval of the views presented, the products used, or the materials exhibited by the Tumor Section or by its Committees or Affiliates. The Tumor Section disclaims any and all liability for injury or other damages resulting to any individual attending the meeting, and for all claims which may arise out of the use of the techniques demonstrated therein by such individuals whether these claims shall be asserted by physicians or any other person. No reproductions of any kind, including audiotape and videotape, may be made of the presentations at the Tumor Section Symposium. The Tumor Section reserves all of its rights to such material, and commercial reproduction is specifically prohibited.

INDUSTRY INFORMATION

EXHIBIT HALL HOURS (NON CME)
Friday, September 8: 9:00 am-3:45 pm
Saturday, September 9: 8:00 am-4:00 pm
Admittance to the Exhibit Hall is by Tumor Section name badge only. Children under the age of 18 are not allowed in the Exhibit Hall.

EXHIBITORS

PARTNERS
- Brainlab
- icotec Medical Inc.

BENEFACTORS
- GammaTile
- Varian, a Siemens Healthineers Company

SPONSORS
- Chimerix
- Elekta Inc.
- Neosoma Inc.

BREAKS WITH EXHIBITORS (NON CME)

FRIDAY
- 10:20-11:05 am
- 2:45-3:30 pm

What's New Session Presented by Elekta Inc., Neosoma Inc.

SATURDAY
- 10:15-11:00 am
- 3:15-4:00 pm

INDUSTRY SPONSORED LUNCH SESSIONS

FRIDAY
- 12:00-1:10 pm

Sponsored by: GammaTile

SATURDAY
- 12:00-1:09 pm

Sponsored by: Brainlab, icotec Medical Inc.
ONLINE REGISTRATION
Go to cns.org/tumor to register online. Visa, MasterCard, or American Express are accepted for payment. Online advance registration is the most immediate and secure method of registration.

MEETING VENUE
The meeting will be held at the Walter E. Washington Convention Center, 801 Mt Vernon Pl NW, Washington, D.C. 20001.

SECURE HOUSING
Hotel reservations for the 2023 Tumor Section Symposium can be reserved in conjunction with the 2023 CNS Annual Meeting. The CNS headquarter hotel is the Marriott Marquis Washington, D.C., and additional hotels and discounted room rates are available upon registration.

Visit cns.org/tumor to review housing availability and book your hotel through MCI, the CNS official housing bureau.

HOTEL CHANGE/CANCELLATION POLICY
The deadline date for new reservations is August 14, 2023, based on availability. Please make any changes or cancellations through the CNS official housing bureau, MCI, through August 14, except for the Grand Hyatt Hotel. You may continue to make changes or cancellations for the Grand Hyatt Hotel through the CNS official housing bureau, MCI, until August 30.

Beginning August 15, 2023
■ All changes, cancellations, or questions regarding your reservation must be made directly with the hotel starting August 15th, 2023, except for the Grand Hyatt Hotel. You may continue to make changes or cancellations for the Grand Hyatt Hotel through the CNS official housing bureau, MCI, until August 30.
■ The deposit will be forfeited if a cancellation notice is not received according to the hotel policy. Your individual hotel’s cancellation policy can be found in your emailed confirmation.

DEPOSIT
A deposit of one night’s room and tax is due at the time your hotel reservation is made. This payment must be submitted with your registration fee and will be charged to the credit card provided.

Please make checks payable to:
CNS Registration and Housing Center
6100 W. Plano Parkway, Suite 3500, Plano, TX 75093.

All rooms are subject to applicable state and local taxes. A small portion of your room rate will be used to help defray the cost of registration and housing services. Hotel reservations requested without a deposit will not be processed.

REGISTRATION RATES

<table>
<thead>
<tr>
<th>Registration Type</th>
<th>Through August 9</th>
<th>After August 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member</td>
<td>$375</td>
<td>$475</td>
</tr>
<tr>
<td>Non-Member</td>
<td>$575</td>
<td>$675</td>
</tr>
<tr>
<td>Resident/Fellow</td>
<td>$100</td>
<td>$200</td>
</tr>
<tr>
<td>Nurse/NP/PA</td>
<td>$150</td>
<td>$250</td>
</tr>
<tr>
<td>Medical Student</td>
<td>$0</td>
<td>$10</td>
</tr>
</tbody>
</table>

Optional Event:
Anniversary Dinner Gala $200 $300

Save $200 total on your registration if you register for the CNS Annual Meeting on September 9–13 and the Tumor Section Symposium on September 8–9. That’s a $100 discount on registration for each meeting. Residents and Fellows receive a $50 discount on registration for each meeting. Offer expires August 9.

Admission to scientific sessions, exhibit hall, poster viewing and meal events provided by the Tumor Section is included with your registration. Admission to the Anniversary Gala is an additional fee.

AIRLINE DISCOUNTS
The Tumor Section is pleased to offer discounts with the following airlines. Discounts are available for flight dates as noted below by airline to and from Washington, D.C. area airports.

United Airlines – www.united.com
Valid dates: September 3–18, 2023
Enter code ZN6W

Delta Airlines – www.delta.com
Valid dates: September 1–20, 2023
Enter code NM2GW

CANCELLATIONS/REFUNDS
Requests for registration cancellation must be made in writing to:
Tumor Section Symposium CNS Registration and Housing Center
6100 Plano Pkwy., Suite 3500, Plano, TX 75093
Email: cns@mcievents.com
Phone: 972-349-5539
Fax: 972-349-7715

All qualifying refunds will be processed following the 2023 Tumor Section meeting. Please allow four to six weeks for processing.

Refunds will be made in accordance with the following schedule:
■ Full registration refunds, less a $100 processing fee, will be granted if written requests for cancellation are received by 5:00 pm CST on August 16, 2023.
■ No refunds will be made for cancellations received after August 16, 2023, or for no-shows.